Carbapenemase-producing Enterobacteriaceae

Yohei Doi, David L. Paterson

Research output: Contribution to journalArticle

87 Citations (Scopus)

Abstract

Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the 1990s, but are today encountered routinely in hospitals and other healthcare facilities in many countries including the United States. KPC-producing Klebsiella pneumoniae was the first to emerge and spread globally and is endemic in the United States, Israel, Greece, and Italy. Recently, NDM-producing Enterobacteriaceae and OXA-48-producing K. pneumoniae appear to be disseminating from South Asia and Northern Africa, respectively. They are almost always resistant to all β-lactams including carbapenems and many other classes. Mortality from invasive CPE infections reaches up to 40%. To obtain the maximal benefit from the limited options available, dosing of antimicrobial agents should be optimized based on pharmacokinetic data, especially for colistin and carbapenems. In addition, multiple observational studies have associated combination antimicrobial therapy with lower mortality compared with monotherapy for these infections. The outcomes appear to be especially favorable when patients are treated with a carbapenem and a second agent such as colistin, tigecycline, and gentamicin, but the best approach is yet to be defined.

Original languageEnglish
Pages (from-to)74-84
Number of pages11
JournalSeminars in Respiratory and Critical Care Medicine
Volume36
Issue number1
DOIs
Publication statusPublished - 01-01-2015
Externally publishedYes

Fingerprint

Carbapenems
Enterobacteriaceae
Colistin
Klebsiella pneumoniae
Enterobacteriaceae Infections
Northern Africa
Lactams
Mortality
Greece
Israel
South Africa
Anti-Infective Agents
Gentamicins
Italy
Observational Studies
Pharmacokinetics
Delivery of Health Care
Infection
carbapenemase
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine
  • Critical Care and Intensive Care Medicine

Cite this

@article{ab4c0db6691f44ebb45d6a38c01f3311,
title = "Carbapenemase-producing Enterobacteriaceae",
abstract = "Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the 1990s, but are today encountered routinely in hospitals and other healthcare facilities in many countries including the United States. KPC-producing Klebsiella pneumoniae was the first to emerge and spread globally and is endemic in the United States, Israel, Greece, and Italy. Recently, NDM-producing Enterobacteriaceae and OXA-48-producing K. pneumoniae appear to be disseminating from South Asia and Northern Africa, respectively. They are almost always resistant to all β-lactams including carbapenems and many other classes. Mortality from invasive CPE infections reaches up to 40{\%}. To obtain the maximal benefit from the limited options available, dosing of antimicrobial agents should be optimized based on pharmacokinetic data, especially for colistin and carbapenems. In addition, multiple observational studies have associated combination antimicrobial therapy with lower mortality compared with monotherapy for these infections. The outcomes appear to be especially favorable when patients are treated with a carbapenem and a second agent such as colistin, tigecycline, and gentamicin, but the best approach is yet to be defined.",
author = "Yohei Doi and Paterson, {David L.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1055/s-0035-1544208",
language = "English",
volume = "36",
pages = "74--84",
journal = "Seminars in Respiratory and Critical Care Medicine",
issn = "1069-3424",
publisher = "Thieme Medical Publishers",
number = "1",

}

Carbapenemase-producing Enterobacteriaceae. / Doi, Yohei; Paterson, David L.

In: Seminars in Respiratory and Critical Care Medicine, Vol. 36, No. 1, 01.01.2015, p. 74-84.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Carbapenemase-producing Enterobacteriaceae

AU - Doi, Yohei

AU - Paterson, David L.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the 1990s, but are today encountered routinely in hospitals and other healthcare facilities in many countries including the United States. KPC-producing Klebsiella pneumoniae was the first to emerge and spread globally and is endemic in the United States, Israel, Greece, and Italy. Recently, NDM-producing Enterobacteriaceae and OXA-48-producing K. pneumoniae appear to be disseminating from South Asia and Northern Africa, respectively. They are almost always resistant to all β-lactams including carbapenems and many other classes. Mortality from invasive CPE infections reaches up to 40%. To obtain the maximal benefit from the limited options available, dosing of antimicrobial agents should be optimized based on pharmacokinetic data, especially for colistin and carbapenems. In addition, multiple observational studies have associated combination antimicrobial therapy with lower mortality compared with monotherapy for these infections. The outcomes appear to be especially favorable when patients are treated with a carbapenem and a second agent such as colistin, tigecycline, and gentamicin, but the best approach is yet to be defined.

AB - Carbapenemase-producing Enterobacteriaceae (CPE) were almost nonexistent up to the 1990s, but are today encountered routinely in hospitals and other healthcare facilities in many countries including the United States. KPC-producing Klebsiella pneumoniae was the first to emerge and spread globally and is endemic in the United States, Israel, Greece, and Italy. Recently, NDM-producing Enterobacteriaceae and OXA-48-producing K. pneumoniae appear to be disseminating from South Asia and Northern Africa, respectively. They are almost always resistant to all β-lactams including carbapenems and many other classes. Mortality from invasive CPE infections reaches up to 40%. To obtain the maximal benefit from the limited options available, dosing of antimicrobial agents should be optimized based on pharmacokinetic data, especially for colistin and carbapenems. In addition, multiple observational studies have associated combination antimicrobial therapy with lower mortality compared with monotherapy for these infections. The outcomes appear to be especially favorable when patients are treated with a carbapenem and a second agent such as colistin, tigecycline, and gentamicin, but the best approach is yet to be defined.

UR - http://www.scopus.com/inward/record.url?scp=84922169860&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922169860&partnerID=8YFLogxK

U2 - 10.1055/s-0035-1544208

DO - 10.1055/s-0035-1544208

M3 - Article

C2 - 25643272

AN - SCOPUS:84922169860

VL - 36

SP - 74

EP - 84

JO - Seminars in Respiratory and Critical Care Medicine

JF - Seminars in Respiratory and Critical Care Medicine

SN - 1069-3424

IS - 1

ER -